EP1347980A4 - Compounds specific to adenosine-a1,-a2a, and- a3-receptor and uses thereof - Google Patents
Compounds specific to adenosine-a1,-a2a, and- a3-receptor and uses thereofInfo
- Publication number
- EP1347980A4 EP1347980A4 EP01997029A EP01997029A EP1347980A4 EP 1347980 A4 EP1347980 A4 EP 1347980A4 EP 01997029 A EP01997029 A EP 01997029A EP 01997029 A EP01997029 A EP 01997029A EP 1347980 A4 EP1347980 A4 EP 1347980A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- adenosine
- receptor
- compounds specific
- compounds
- specific
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Otolaryngology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US728616 | 2000-12-01 | ||
US09/728,316 US6680322B2 (en) | 1999-12-02 | 2000-12-01 | Compounds specific to adenosine A1 receptors and uses thereof |
US09/728,607 US6664252B2 (en) | 1999-12-02 | 2000-12-01 | 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof |
US09/728,616 US7160890B2 (en) | 1999-12-02 | 2000-12-01 | Compounds specific to adenosine A3 receptor and uses thereof |
US728316 | 2000-12-01 | ||
US728607 | 2000-12-01 | ||
PCT/US2001/045280 WO2002057267A1 (en) | 2000-12-01 | 2001-11-30 | Compounds specific to adenosine a1, a2a, and a3 receptor and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1347980A1 EP1347980A1 (en) | 2003-10-01 |
EP1347980A4 true EP1347980A4 (en) | 2005-02-09 |
Family
ID=27419112
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01997029A Ceased EP1347980A4 (en) | 2000-12-01 | 2001-11-30 | Compounds specific to adenosine-a1,-a2a, and- a3-receptor and uses thereof |
Country Status (20)
Country | Link |
---|---|
EP (1) | EP1347980A4 (en) |
JP (1) | JP4579497B2 (en) |
CN (1) | CN1263757C (en) |
AP (1) | AP1893A (en) |
AU (1) | AU2002248151B2 (en) |
BR (1) | BR0115847A (en) |
CA (1) | CA2430577A1 (en) |
CZ (1) | CZ20031831A3 (en) |
EA (1) | EA007254B1 (en) |
HU (1) | HUP0400692A3 (en) |
IL (1) | IL155962A0 (en) |
ME (1) | MEP35308A (en) |
MX (1) | MXPA03004717A (en) |
NO (1) | NO327207B1 (en) |
NZ (1) | NZ525885A (en) |
OA (1) | OA13295A (en) |
PL (1) | PL363245A1 (en) |
WO (1) | WO2002057267A1 (en) |
YU (1) | YU42703A (en) |
ZA (1) | ZA200303729B (en) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5090531A (en) * | 1990-01-10 | 1992-02-25 | Lord Corporation | Electrophoretic fluid differential |
BR9911612A (en) | 1998-06-02 | 2001-02-06 | Osi Pharm Inc | Pyrrole [2,3d] pyrimidine compositions and their uses |
US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
DE10148883A1 (en) | 2001-10-04 | 2003-04-10 | Merck Patent Gmbh | New fused bi- or tricyclic pyrimidine derivatives, are phosphodiesterase V inhibitors useful e.g. for treating impotence, cardiovascular disorders, inflammation or tumors |
JP2005529062A (en) | 2001-11-30 | 2005-09-29 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | Compounds specific for adenosine A1 and A3 receptors and uses thereof |
EP2198867A1 (en) * | 2001-12-07 | 2010-06-23 | Vertex Pharmaceuticals, Inc. | Pyrimidine-based compounds useful as GSK-3 inhibitors |
CN101973998A (en) | 2001-12-20 | 2011-02-16 | Osi药物公司 | Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use |
EP1465631B1 (en) | 2001-12-20 | 2010-02-24 | OSI Pharmaceuticals, Inc. | Pyrimidine a2b selective antagonist compounds, their synthesis and use |
JP2006512313A (en) * | 2002-10-31 | 2006-04-13 | アムジェン インコーポレイテッド | Anti-inflammatory agent |
HUP0203976A3 (en) * | 2002-11-15 | 2004-08-30 | Sanofi Aventis | Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them |
MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
UY29177A1 (en) | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | SUBSTITUTED DERIVATIVES OF PURINA, PURINONA AND DEAZAPURINA, COMPOSITIONS THAT CONTAIN METHODS FOR THEIR PREPARATION AND ITS USES |
WO2007125321A2 (en) | 2006-04-25 | 2007-11-08 | Astex Therapeutics Limited | Purine and deazapurine derivatives as pharmaceutical compounds |
US20070260203A1 (en) * | 2006-05-04 | 2007-11-08 | Allergan, Inc. | Vasoactive agent intraocular implant |
TW200808819A (en) * | 2006-06-19 | 2008-02-16 | Solvay Pharm Gmbh | Use of adenosine A1 antagonists in radiocontrast media induced nephrophaty |
RS53552B1 (en) | 2007-10-11 | 2015-02-27 | Astrazeneca Ab | Pyrrolo[2,3-d]pyrimidin derivatives as protein kinase b inhibitors |
CN101965350A (en) | 2008-01-11 | 2011-02-02 | 纳科法尔马有限公司 | New pyrazolo [3,4-d] pyrimidine derivatives as carcinostatic agent |
AR070127A1 (en) | 2008-01-11 | 2010-03-17 | Novartis Ag | PIRROLO - PIRIMIDINAS AND PIRROLO -PIRIDINAS |
AU2012235902B2 (en) | 2011-04-01 | 2015-08-27 | Astrazeneca Ab | Therapeutic treatment |
JP6309454B2 (en) | 2011-11-30 | 2018-04-11 | アストラゼネカ アクチボラグ | Combined cancer treatment |
AU2013204533B2 (en) | 2012-04-17 | 2017-02-02 | Astrazeneca Ab | Crystalline forms |
EP2858995A1 (en) * | 2012-06-07 | 2015-04-15 | F. Hoffmann-La Roche AG | Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase |
JP6461118B2 (en) * | 2013-06-21 | 2019-01-30 | ゼニス・エピジェネティクス・リミテッドZenith Epigenetics Ltd. | Novel substituted bicyclic compounds as bromodomain inhibitors |
NZ714669A (en) | 2013-06-21 | 2021-07-30 | Zenith Epigenetics Ltd | Novel bicyclic bromodomain inhibitors |
EA201690087A1 (en) | 2013-07-31 | 2016-08-31 | Зенит Эпидженетикс Корп. | NEW QUINAZOLINONS AS BROMOMODENIAL INHIBITORS |
WO2016087936A1 (en) | 2014-12-01 | 2016-06-09 | Zenith Epigenetics Corp. | Substituted pyridinones as bromodomain inhibitors |
CA2966303A1 (en) | 2014-12-01 | 2016-06-09 | Zenith Epigenetics Ltd. | Substituted pyridines as bromodomain inhibitors |
CA2966449A1 (en) | 2014-12-11 | 2016-06-16 | Zenith Epigenetics Ltd. | Substituted heterocycles as bromodomain inhibitors |
CN107406438B (en) | 2014-12-17 | 2021-05-14 | 恒翼生物医药科技(上海)有限公司 | Inhibitors of bromodomains |
CN108349977B (en) * | 2015-01-20 | 2021-05-25 | 无锡福祈制药有限公司 | JAK inhibitors |
ES2734048T3 (en) | 2015-04-29 | 2019-12-04 | Wuxi Fortune Pharmaceutical Co Ltd | Janus kinase inhibitors (JAK) |
EA036063B1 (en) | 2015-05-29 | 2020-09-22 | Уси Форчун Фармасьютикал Ко., Лтд | Janus kinase inhibitor |
CN105771672B (en) * | 2016-04-18 | 2018-03-02 | 天津工业大学 | A kind of antipollution antibiotic aromatic polyamide reverse osmosis composite film and preparation method |
CN108570054B (en) * | 2017-03-07 | 2021-07-16 | 广州再极医药科技有限公司 | Aminopyrimidine five-membered heterocyclic compound, intermediate thereof, preparation method, pharmaceutical composition and application |
CN108017584B (en) * | 2017-06-20 | 2021-03-23 | 南开大学 | A3Small molecule antagonists of adenosine receptors |
BR112020024700A2 (en) * | 2018-06-04 | 2021-03-02 | Exscientia Ltd | pyrazolopyrimidine compounds as adenosine receptor antagonists |
CN110128316B (en) * | 2019-05-22 | 2021-08-31 | 北京大学深圳研究生院 | Preparation method of 5-substituted beta-proline and derivatives thereof |
CN110272373B (en) * | 2019-07-02 | 2022-07-29 | 天津国际生物医药联合研究院 | Selective adenosine A 1 Receptor antagonists and uses thereof |
CN114085178A (en) * | 2021-12-29 | 2022-02-25 | 苏州楚凯药业有限公司 | Preparation method of 4-methyl-1-propyl-2-amino-1H-pyrrole-3-nitrile |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5780450A (en) * | 1995-11-21 | 1998-07-14 | Alcon Laboratories, Inc. | Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage |
WO1999062518A1 (en) * | 1998-06-02 | 1999-12-09 | Osi Pharmaceuticals, Inc. | PYRROLO[2,3d]PYRIMIDINE COMPOSITIONS AND THEIR USE |
WO2001039777A1 (en) * | 1999-12-02 | 2001-06-07 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine a1 a2a, and a3 receptors and uses thereof |
WO2003048120A2 (en) * | 2001-11-30 | 2003-06-12 | Osi Pharmaceuticals, Inc. | 2-aryl pyrrologpyrimidines for a1 and a3 receptors |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0674641T3 (en) * | 1992-12-17 | 1999-09-27 | Pfizer | Pyrrolopyrimidines as CRF antagonists |
-
2001
- 2001-11-30 PL PL01363245A patent/PL363245A1/en not_active Application Discontinuation
- 2001-11-30 JP JP2002557944A patent/JP4579497B2/en not_active Expired - Fee Related
- 2001-11-30 HU HU0400692A patent/HUP0400692A3/en unknown
- 2001-11-30 NZ NZ525885A patent/NZ525885A/en active IP Right Revival
- 2001-11-30 YU YU42703A patent/YU42703A/en unknown
- 2001-11-30 BR BR0115847-3A patent/BR0115847A/en not_active Application Discontinuation
- 2001-11-30 MX MXPA03004717A patent/MXPA03004717A/en active IP Right Grant
- 2001-11-30 EA EA200300628A patent/EA007254B1/en not_active IP Right Cessation
- 2001-11-30 ME MEP-353/08A patent/MEP35308A/en unknown
- 2001-11-30 OA OA1200300148A patent/OA13295A/en unknown
- 2001-11-30 AU AU2002248151A patent/AU2002248151B2/en not_active Ceased
- 2001-11-30 AP APAP/P/2003/002807A patent/AP1893A/en active
- 2001-11-30 IL IL15596201A patent/IL155962A0/en unknown
- 2001-11-30 WO PCT/US2001/045280 patent/WO2002057267A1/en active IP Right Grant
- 2001-11-30 CZ CZ20031831A patent/CZ20031831A3/en unknown
- 2001-11-30 CA CA002430577A patent/CA2430577A1/en not_active Abandoned
- 2001-11-30 EP EP01997029A patent/EP1347980A4/en not_active Ceased
- 2001-11-30 CN CNB018224601A patent/CN1263757C/en not_active Expired - Fee Related
-
2003
- 2003-05-14 ZA ZA200303729A patent/ZA200303729B/en unknown
- 2003-06-02 NO NO20032482A patent/NO327207B1/en not_active IP Right Cessation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5780450A (en) * | 1995-11-21 | 1998-07-14 | Alcon Laboratories, Inc. | Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage |
WO1999062518A1 (en) * | 1998-06-02 | 1999-12-09 | Osi Pharmaceuticals, Inc. | PYRROLO[2,3d]PYRIMIDINE COMPOSITIONS AND THEIR USE |
WO2001039777A1 (en) * | 1999-12-02 | 2001-06-07 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine a1 a2a, and a3 receptors and uses thereof |
WO2003048120A2 (en) * | 2001-11-30 | 2003-06-12 | Osi Pharmaceuticals, Inc. | 2-aryl pyrrologpyrimidines for a1 and a3 receptors |
Non-Patent Citations (1)
Title |
---|
See also references of WO02057267A1 * |
Also Published As
Publication number | Publication date |
---|---|
EA007254B1 (en) | 2006-08-25 |
CA2430577A1 (en) | 2002-07-25 |
JP4579497B2 (en) | 2010-11-10 |
NO20032482D0 (en) | 2003-06-02 |
NZ525885A (en) | 2005-01-28 |
MEP35308A (en) | 2011-02-10 |
HUP0400692A2 (en) | 2004-07-28 |
CZ20031831A3 (en) | 2004-05-12 |
JP2004517896A (en) | 2004-06-17 |
IL155962A0 (en) | 2003-12-23 |
OA13295A (en) | 2007-04-13 |
AU2002248151B2 (en) | 2008-02-21 |
EP1347980A1 (en) | 2003-10-01 |
PL363245A1 (en) | 2004-11-15 |
ZA200303729B (en) | 2004-05-14 |
WO2002057267A1 (en) | 2002-07-25 |
NO20032482L (en) | 2003-07-28 |
AP2003002807A0 (en) | 2003-06-30 |
HUP0400692A3 (en) | 2007-09-28 |
CN1263757C (en) | 2006-07-12 |
CN1489590A (en) | 2004-04-14 |
YU42703A (en) | 2006-03-03 |
MXPA03004717A (en) | 2004-06-30 |
AP1893A (en) | 2008-09-23 |
EA200300628A1 (en) | 2003-12-25 |
BR0115847A (en) | 2004-02-25 |
NO327207B1 (en) | 2009-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1347980A4 (en) | Compounds specific to adenosine-a1,-a2a, and- a3-receptor and uses thereof | |
PL357210A1 (en) | Novel use | |
EP1341554A4 (en) | Colostrum-based composition | |
GB0026467D0 (en) | Compound, composition and use | |
EP1270611A4 (en) | Composition | |
GB2364338B (en) | Improvements relating to construction | |
AU2001287852A8 (en) | Composition | |
GB0005301D0 (en) | Compound, composition and use | |
GB0028814D0 (en) | Improvements relating to biosorbtion | |
GB0005299D0 (en) | Compound, compositions and use | |
GB0007762D0 (en) | Composition | |
GB0027783D0 (en) | Novel use | |
GB0017107D0 (en) | Improvements to velodromes | |
GB0025715D0 (en) | Improvements relating to haribrushes | |
GB0011593D0 (en) | Compounds and their uses | |
GB0011591D0 (en) | Compounds and their uses | |
GB0011594D0 (en) | Compounds and their uses | |
GB0011592D0 (en) | Compounds and their uses | |
GB0024701D0 (en) | Novel Use | |
GB0007856D0 (en) | Novel use | |
GB0020001D0 (en) | Novel use | |
GB0024718D0 (en) | Novel use | |
GB0005168D0 (en) | Novel use | |
GB0007858D0 (en) | Novel use | |
GB0031067D0 (en) | Novel use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20030630 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1058933 Country of ref document: HK |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20041230 |
|
17Q | First examination report despatched |
Effective date: 20071004 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R003 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
18R | Application refused |
Effective date: 20111009 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1058933 Country of ref document: HK |